These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7517542)

  • 1. Prostatic cancer and BPH.
    Brown SA
    Postgrad Med; 1994 Jul; 96(1):24-5. PubMed ID: 7517542
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].
    Hübler J; Jávor A
    Orv Hetil; 1993 Jul; 134(28):1529-32. PubMed ID: 7688112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostate-specific antigen and prostatic cancer].
    Otnes B; Tveter KJ
    Tidsskr Nor Laegeforen; 1994 Mar; 114(7):829. PubMed ID: 7516585
    [No Abstract]   [Full Text] [Related]  

  • 5. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection in BPH patients.
    Puppo P; Perachino M; Ricciotti G; Bozzo W
    Arch Esp Urol; 1994 Nov; 47(9):867-72. PubMed ID: 7530942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study supports PSA velocity risk count.
    Fillon M
    J Natl Cancer Inst; 2012 Jul; 104(14):1042-3. PubMed ID: 22781432
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of BPH: educating patients about PSA.
    Malvea BP
    Am Fam Physician; 1996 Mar; 53(4):1080, 1082. PubMed ID: 8629559
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB; Oesterling JE
    Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL; Deng FM; Feng T
    Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 16. [The evaluation of the ratio of free and total serum prostate-specific antigen as an additional method in the diagnosis of prostatic cancer].
    Reznikov IuP; Mazanov GP; Sedova TN
    Urol Nefrol (Mosk); 1996; (6):41-3. PubMed ID: 9036610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
    Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
    Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.